Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 16,119 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorders Clear all
Recruiting No phase listed Observational

COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients

NCT05972343
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
Cryoablation
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

NCT03997968
View directory record Official record
Conditions
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
Interventions
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Drug
Lead sponsor
Cyteir Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 28, 2026, 5:27 PM EDT
Recruiting Phase 3 Interventional

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

NCT06654882
View directory record Official record
Conditions
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Interventions
TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab, Tofacitinib
Drug
Lead sponsor
Duke University
Other
Eligibility
2 Years to 21 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 28, 2026, 5:27 PM EDT
Not listed No phase listed Observational

Incorporation of AlloMaxTM in Breast Reconstruction Ver8-15-12

NCT01679223
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 9, 2015 · Synced Oct 28, 2026, 5:27 PM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

NCT05645380
View directory record Official record
Conditions
Triple Negative Breast Cancer, Breast Cancer
Interventions
Carboplatin, Docetaxel, Doxorubicin, Cyclophosphamide, Pembrolizumab
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Fairway, Kansas • Kansas City, Kansas • Overland Park, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 28, 2026, 5:27 PM EDT
Recruiting No phase listed Observational

Remibrutinib in Real-world Clinical Practice - a US Sub-study

NCT07358780
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Kirksville, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 28, 2026, 5:27 PM EDT
Terminated Not applicable Interventional Results available

LUPUS Brain: tACS to Target the Neurophysiology of Depression, Cognitive Deficits, and Pain in Patients With SLE

NCT04141046
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Depression
Interventions
XCSITE100 Stimulator - Individualized theta-tACS, XCSITE100 Stimulator - Individualized alpha-tACS, XCSITE100 Stimulator - Active Sham
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Not applicable Interventional

CBPR - BRCA Genetic Testing Among Orthodox Jews

NCT03624088
View directory record Official record
Conditions
Breast Cancer
Interventions
RealRisks
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
25 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Phase 3 Interventional Results available

Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921

NCT03298061
View directory record Official record
Conditions
Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis
Interventions
Mepolizumab, Prednisolone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
14
States / cities
Denver, Colorado • Bethesda, Maryland • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 28, 2026, 5:27 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

NCT00461773
View directory record Official record
Conditions
Hormone-Sensitive Breast Cancer, Breast Cancer
Interventions
Letrozole, Bevacizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Not applicable Interventional

Coping Skills Training for Early Rheumatoid Arthritis

NCT00056394
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Comprehensive Coping Skills Training, Arthritis Education Sessions, Standard Care
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Phase 1 Interventional

Study of Ruxolitinib Cream in Children With Atopic Dermatitis

NCT05034822
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 11 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Gilbert, Arizona • Hot Springs, Arkansas • Anaheim, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 28, 2026, 5:27 PM EDT
Active, not recruiting Phase 1 Interventional

'ADVANCE' (A Pilot Trial)

NCT03858322
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, Cyclophosphamide, Carboplatin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
70 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • Milford, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 28, 2026, 5:27 PM EDT
Not listed Not applicable Interventional

Intraoperative Boost Radiotherapy With Electrons (IOERT) Followed By Hypofractionated Whole-Breast Irradiation (WBRT)

NCT01295723
View directory record Official record
Conditions
Invasive Lobular and Ductal Carcinoma
Interventions
Hypofractionated Whole Breast Radiation Therapy, Intraoperative Electron Radiation Therapy
Radiation
Lead sponsor
St. Joseph Hospital of Orange
Other
Eligibility
40 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 28, 2026, 5:27 PM EDT
Terminated Phase 1 Interventional

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

NCT03597282
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
NEO-PV-01, Nivolumab, Adjuvant, APX005M, ipilimumab
Biological · Other
Lead sponsor
BioNTech US Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Not applicable Interventional

A Lifestyle Intervention for Breast Cancer Survivors

NCT01819324
View directory record Official record
Conditions
Breast Cancer
Interventions
Targeting the Teachable Moment, Standardized Lifestyle Management
Behavioral
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enhancing Cancer Prevention and Control Pathways-Native Health Initiative

NCT04259762
View directory record Official record
Conditions
Cancer, Breast, Cancer, Colon, Cancer, Cervix
Interventions
Aim 8 (INT, Pilot Test): Breast, Colorectal, and Cervical Cancer Screening Cognitive-Behavioral Interventions
Other
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
21 Years to 75 Years
Enrollment
508 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Phase 3 Interventional Results available

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

NCT04180488
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Dupilumab SAR231893, Placebo, non sedating H1-antihistamine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 80 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 28, 2026, 5:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Antioxidants on Skin Blood Flow-BH4

NCT03680573
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction
Interventions
Control: Lacated Ringers, Apocynin, Allopurinol, BH4, NG Nitro L Arginine Methyl Ester, Sodium Nitroprusside, Acetyl-ß-methylcholine chloride
Drug
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 28, 2026, 5:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pregnancy With Morquio Syndrome - What Are Patients' Perspectives and Has ERT Changed Them?

NCT03150069
View directory record Official record
Conditions
Morquio Disease, MPS - Mucopolysaccharidosis
Interventions
Interview
Other
Lead sponsor
Emory University
Other
Eligibility
15 Years to 100 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 28, 2026, 5:27 PM EDT
Recruiting No phase listed Observational

Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

NCT01257269
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura, Familial Thrombotic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Congenital, Upshaw-Schulman Syndrome
Interventions
Observation
Other
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Other
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2030
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 28, 2026, 5:27 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")

NCT03400254
View directory record Official record
Conditions
Breast Cancer
Interventions
Hydroxychloroquine (HCQ), Gedatolisib
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 28, 2026, 5:27 PM EDT
Recruiting Early Phase 1 Interventional

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

NCT06435351
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Leukapheresis, Dendritic Cell (DC) Vaccine
Procedure · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 28, 2026, 5:27 PM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer

NCT00925652
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab, Cyclophosphamide, Methotrexate, Lifestyle: Diet, Lifestyle: Diet+Exercise
Drug · Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
9
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 28, 2026, 5:27 PM EDT